gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SNOAHealthcareSurgical Instruments

Sonoma Pharmaceuticals, Inc. Common Stock (SNOA)

$1.11−2.63%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$1.11▼ 70.48% in range
Nov 4, 2025Low $1.01 · High $3.80Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Sonoma Pharmaceuticals closed at $1.11 on Nov 4, down 2.63%, 70.8% below its 52-week closing high. Volume of 10.0K shares was 0.24× its 20-day average (below normal).

Split-adjusted performance: -9.8% over one month, -6.7% over six months, -70.6% over one year.

In the quarter ended Jun 30, 2026, revenue was $6.41M, up 59.6% from a year earlier, with a net margin of -5.2%.

Short interest was 108.8K shares at the Oct 15 settlement, down 33.9% from the prior report (2.3% of float, 2.8 days to cover).

Market cap$5.3M4.8M shares
Revenue · quarter$6.4M+59.6% YoY
Diluted EPS$-0.09—
P/E · TTM—P/S 0.2×
Net margin-5.2%Gross 40.2%
Dividend yieldNone
52-week range1.01 – 3.80−70.8% from high
Volume10.0K0.24× 20-day avg
Volatility · 60d40.4%Annualised
Short % of float2.3%2.8 days to cover
Net cash$5.2MCash $5.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −2.6%1M −9.8%3M −11.2%6M −6.7%YTD −69.5%1Y −70.6%3Y −69.2%5Y −99.1%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum49
Revenue growth94
Net margin55
Value (low P/E)—
Size12

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short108.8K−33.9% vs prior
Days to cover2.8Settled Oct 15
% of float2.3%
Short vol. 10d27.0%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SNOASonoma Pharmaceuticals$1.11−2.63%−6.7%+59.6%−5.2%—$5.3M
TNONTenon Medical$1.91+1.06%−92.7%+126.8%−316.7%—$5.1MCompare
INBSIntelligent Bio Solutions$1.75−1.13%−27.4%+35.8%−341.0%—$5.8MCompare
NVNOenVVeno Medical$7.00−2.43%−30.5%———$4.9MCompare
CNSYCerenome$0.8916−31.42%————$6.8MCompare
AEMDAETHLON MEDICAL$5.75−0.86%−51.7%———$4.1MCompare
NMTCNeuroOne Medical Technologies$0.9500−3.06%−77.9%+16.3%−101.7%—$8.7MCompare
CODXCo-Diagnostics$0.3614−4.89%—+2.0%−3782.4%—$3.2MCompare
AMIXAutonomix Medical$1.61−3.01%−80.1%———$3.2MCompare

News about Sonoma Pharmaceuticals

All news →

No recent articles focused on Sonoma Pharmaceuticals.

Quick answers

What does Sonoma Pharmaceuticals do?
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions.
What is SNOA's market cap?
$5.32M, based on the Nov 4 close of $1.11.
Does Sonoma Pharmaceuticals pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SNOA is sold short?
108.8K shares, 2.3% of float, as of Oct 15, 2026.
What sector is SNOA in?
Healthcare, in the Surgical Instruments industry.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.

HQ: Boulder, CO260 employeesListed Jan 25, 2007sonomapharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology